MILESTONE PHARMACEUTICALS IN (MIST) Stock Price & Overview
NASDAQ:MIST • CA59935V1076
Current stock price
The current stock price of MIST is 1.52 USD. Today MIST is up by 10.14%. In the past month the price decreased by -3.8%. In the past year, price increased by 97.07%.
MIST Key Statistics
- Market Cap
- 129.458M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.81
- Dividend Yield
- N/A
MIST Stock Performance
MIST Stock Chart
MIST Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MIST. When comparing the yearly performance of all stocks, MIST is one of the better performing stocks in the market, outperforming 86.58% of all stocks.
MIST Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MIST. Both the profitability and financial health of MIST have multiple concerns.
MIST Earnings
On March 20, 2026 MIST reported an EPS of -0.18 and a revenue of 1.55M. The company missed EPS expectations (-10.29% surprise).
MIST Forecast & Estimates
11 analysts have analysed MIST and the average price target is 6.73 USD. This implies a price increase of 342.89% is expected in the next year compared to the current price of 1.52.
MIST Groups
Sector & Classification
MIST Financial Highlights
Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS decreased by -17.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.53% | ||
| ROE | -150.97% | ||
| Debt/Equity | 1.37 |
MIST Ownership
MIST Latest News, Press Relases and Analysis
MIST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.52 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.69 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.838B | ||
| PFE | PFIZER INC | 9.32 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.37 | 121.374B | ||
| ZTS | ZOETIS INC | 16.71 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 28.018B | ||
| VTRS | VIATRIS INC | 5.35 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.44 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MIST
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Company Info
IPO: 2019-05-09
MILESTONE PHARMACEUTICALS IN
420-1111 boul. Dr.-Frederik-Philips
MONTREAL QUEBEC H4M 2X6 CA
CEO: Joseph Oliveto
Employees: 33
Phone: 15143360444
MILESTONE PHARMACEUTICALS IN / MIST FAQ
What does MILESTONE PHARMACEUTICALS IN do?
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
What is the stock price of MILESTONE PHARMACEUTICALS IN today?
The current stock price of MIST is 1.52 USD. The price increased by 10.14% in the last trading session.
Does MILESTONE PHARMACEUTICALS IN pay dividends?
MIST does not pay a dividend.
How is the ChartMill rating for MILESTONE PHARMACEUTICALS IN?
MIST has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of MILESTONE PHARMACEUTICALS IN (MIST) based on its PE ratio?
MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
What is the employee count for MIST stock?
MILESTONE PHARMACEUTICALS IN (MIST) currently has 33 employees.
Who owns MILESTONE PHARMACEUTICALS IN?
You can find the ownership structure of MILESTONE PHARMACEUTICALS IN (MIST) on the Ownership tab.